Roth Capital Has Pessimistic Outlook of PolyPid Q3 Earnings

Key Points

• Roth Capital has reduced its Q3 2025 earnings forecast for PolyPid Ltd. to ($0.69) per share, down from a previous estimate of ($0.35).
• The consensus full-year earnings forecast for PolyPid has been set at ($1.79) per share, reflecting broader concerns over the company's financial performance.
• Despite the negative outlook, Roth Capital maintains a "Buy" rating on PolyPid's stock, which has seen a moderate buy consensus with a target price of $12.40.

PolyPid Ltd. (NASDAQ:PYPD - Free Report) - Investment analysts at Roth Capital reduced their Q3 2025 earnings per share (EPS) estimates for shares of PolyPid in a report released on Wednesday, August 13th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings of ($0.69) per share for the quarter, down from their prior forecast of ($0.35). Roth Capital has a "Buy" rating on the stock. The consensus estimate for PolyPid's current full-year earnings is ($1.79) per share. Roth Capital also issued estimates for PolyPid's Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.81) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.73) EPS.

PolyPid (NASDAQ:PYPD - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.25).

A number of other equities research analysts have also weighed in on the company. Craig Hallum reaffirmed a "buy" rating and set a $13.00 target price (down from $15.00) on shares of PolyPid in a research report on Thursday, August 14th. JMP Securities decreased their target price on PolyPid from $16.00 to $14.00 and set a "market outperform" rating for the company in a research report on Tuesday, June 17th. Wall Street Zen lowered PolyPid from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of PolyPid in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $12.40.

PolyPid Stock Performance

NASDAQ PYPD traded up $0.02 on Monday, reaching $3.53. 59,247 shares of the stock traded hands, compared to its average volume of 73,991. The company has a fifty day moving average price of $3.50 and a 200-day moving average price of $3.06. The company has a market cap of $56.12 million, a price-to-earnings ratio of -0.92 and a beta of 1.40. PolyPid has a 12 month low of $2.30 and a 12 month high of $3.93.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PYPD. J. Goldman & Co LP purchased a new stake in PolyPid during the 4th quarter valued at about $391,000. AIGH Capital Management LLC grew its stake in PolyPid by 13.6% during the 1st quarter. AIGH Capital Management LLC now owns 940,381 shares of the company's stock valued at $2,548,000 after purchasing an additional 112,514 shares during the last quarter. Finally, Lumbard & Kellner LLC purchased a new stake in PolyPid during the 2nd quarter valued at about $135,000. 26.47% of the stock is owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.